HCPLive Network

American Heart Association 2012 | AHA 2012

According to the AHA, “Scientific Sessions is the leading cardiovascular meeting in the country with over 17,000 professionals attending annually, and over 22,000 total attendees, as reported by the Healthcare Convention and Exhibitor’s Association. Scientific Sessions is the American Heart Association's largest gathering of scientists and healthcare professionals devoted to the science of cardiovascular disease and stroke and the care of patients suffering from these diseases. Programming is designed to improve patient care by communicating the most timely and significant advances in prevention, diagnosis and treatment of cardiovascular disease from many different perspectives.
AHA 2012 - Day 4
Results from a substudy of the PLATO trial show that patients with extensive CAD and high rates of recurrent cardiovascular events, death, and bleeding may benefit from treatment with ticagrelor.
Results from the RELAX-AHF show serelaxin reduces cardiovascular deaths and improves symptoms in patients with heart failure.
A substudy of the PLATO trial reveals that treatment with ticagrelor reduces cardiovascular death, myocardial infarction, and stroke in some patients with non-ST-elevation acute coronary syndrome.
AHA 2012 - Day 3
New research presented at the American Heart Association 2012 Scientific Sessions reveals that although the number of cardiovascular-related deaths increases during the winter months in the US, the rate increase is consistent across climates.
Many young adults age 18-24 with high blood pressure remain undiagnosed with hypertension, even after long-term physician care.
Study results presented at the American Heart Association 2012 Scientific Sessions show that visible signs of aging such as baldness and yellow fatty deposits around the eye are predictors for heart attack and heart disease risk.
Reprogramming the firing settings for an implantable cardioverter-defibrillator in patients with heart disease reduces inappropriate firings and reduces death, according to a study published online Nov. 6 in the New England Journal of Medicine to coincide with presentation at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.
Subcutaneously administered AMG145, a monoclonal antibody to plasma proprotein convertase subtilisin/kexin type 9, correlates with significant reductions in low-density lipoprotein cholesterol levels in patients who are intolerant to statins due to muscle-related side effects, according to research published online Nov. 5 in the Journal of the American Medical Association to coincide with presentation at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.
AHA 2012 - Day 2
Infusion of CSL112 (apolipoprotein A-1), the active protein of high-density lipoprotein, induces key biomarkers in the initial steps of reverse cholesterol transport in healthy individuals, according to a study presented at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.
Regular social cocaine users have increased systolic blood pressure, stiffer arteries, and thicker heart muscle walls than non-users, according to a small study presented at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.
Men age 50 and older who take multivitamins every day gain no added protection against heart attacks, stroke, or cardiovascular death.
Results from the OPERA trial presented at AHA 2012 show that short-term use of fish oil supplements does not decrease post-operative atrial fibrillation.
Results from the UMPIRE study show that use of fixed-dose combination cardiovascular drugs improve medication adherence and improve blood pressure and cholesterol levels in patients.
M. Amin Karami, PhD, discusses study results presented at AHA 2012 that demonstrated the technical feasibility of using a piezoelectric energy-harvesting device to power a pacemaker.
AHA 2012 - Day 1
Results from a sub-study of the Trial to Assess Chelation Therapy (TACT) that focused on quality of life issues in patients who had previously suffered a heart attack and were treated with chelation therapy reveal no improvements in these patients’ quality of life.
Study results presented at AHA 2012 indicate that revascularization using CABG in diabetic patients with multivessel disease provides better clinical outcomes than PCI and is more cost effective in the long run.
A new experimental device may be able to use converted energy from a patient’s heart to generate enough electricity to fully power a pacemaker.
People with newly diagnosed heart failure are significantly more likely to develop cancer than community controls, according to research presented at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.
Pre Meeting
Click here for information about registration, scheduled events and speakers, and more at AHA 2012.
$AD300x250BB$